Research Analysts Set Expectations for biote Q3 Earnings

Key Points

• B. Riley has revised its Q3 2025 earnings per share (EPS) estimate for biote Corp. from $0.10 to $0.03, maintaining a "Neutral" rating and a price target of $4.00.
• biote recently reported earnings of $0.10 per share for the previous quarter, exceeding the consensus estimate of $0.06, with a revenue of $48.86 million.
• Institutional investors have significantly increased their stakes in biote, with notable increases including a 423.1% boost in holdings by Trexquant Investment LP during the fourth quarter.

biote Corp. (NASDAQ:BTMD - Free Report) - Equities research analysts at B. Riley lowered their Q3 2025 earnings estimates for shares of biote in a report issued on Thursday, August 7th. B. Riley analyst J. Van. Sinderen now anticipates that the company will post earnings per share of $0.03 for the quarter, down from their prior estimate of $0.10. B. Riley currently has a "Neutral" rating and a $4.00 price target on the stock. The consensus estimate for biote's current full-year earnings is $0.75 per share.

biote (NASDAQ:BTMD - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.10 earnings per share for the quarter, topping analysts' consensus estimates of $0.06 by $0.04. The firm had revenue of $48.86 million during the quarter, compared to analysts' expectations of $49.52 million. biote had a net margin of 15.73% and a negative return on equity of 19.71%.

Separately, Wall Street Zen cut shares of biote from a "strong-buy" rating to a "hold" rating in a research report on Saturday.

biote Price Performance

Shares of NASDAQ:BTMD traded down $0.04 during mid-day trading on Friday, reaching $2.88. 239,176 shares of the company were exchanged, compared to its average volume of 133,724. The firm has a market cap of $157.56 million, a price-to-earnings ratio of 3.20 and a beta of 1.21. The firm's 50-day simple moving average is $4.00 and its 200 day simple moving average is $4.02. biote has a 1 year low of $2.87 and a 1 year high of $6.98.

Hedge Funds Weigh In On biote

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP boosted its position in biote by 0.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 681,524 shares of the company's stock valued at $4,211,000 after buying an additional 3,065 shares during the period. Ameriprise Financial Inc. boosted its position in biote by 10.2% in the 4th quarter. Ameriprise Financial Inc. now owns 36,214 shares of the company's stock valued at $224,000 after buying an additional 3,351 shares during the period. Wells Fargo & Company MN boosted its position in biote by 49.9% in the 4th quarter. Wells Fargo & Company MN now owns 12,742 shares of the company's stock valued at $79,000 after buying an additional 4,243 shares during the period. Sei Investments Co. boosted its position in biote by 56.4% in the 4th quarter. Sei Investments Co. now owns 18,321 shares of the company's stock valued at $113,000 after buying an additional 6,605 shares during the period. Finally, CWM LLC boosted its position in biote by 952.7% in the 2nd quarter. CWM LLC now owns 8,674 shares of the company's stock valued at $35,000 after buying an additional 7,850 shares during the period. Hedge funds and other institutional investors own 21.68% of the company's stock.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.